AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
famciclovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals bicyclic heterocycle compounds | 1128 | 104227-87-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An aminopurine derivative and prodrug of penciclovir which is a competitive inhibitor of herpes simplex 2 DNA polymerase. It is used to treat HERPES SIMPLEX VIRUS INFECTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.75 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 250 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 77.80 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 77 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.153 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.254 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 10.351 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 110.154 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 93.690 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 90.980 | % | High | 1 |
| herg | hERG pIC50 | 4.140 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 891.251 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 243.781 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 93.170 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK9,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,MARK4,PDK1,PDK2,PIK3CA,PIK3CD,PRKDC,SIK2 | 20 | |||
| kinase-selectivity-class | AXL,CDK16,CDK9,MAP3K21,PIK3CD,SIK2 | 6 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 15.631 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 445.656 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 95.450 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.272 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 92.800 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 116.950 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 98.300 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 95.310 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 928.966 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 16, 2008 | PMDA | ASAHI KASEI PHARMA CORPORATION | |
| June 29, 1994 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Aplastic anaemia | 39.36 | 19.26 | 16 | 3541 | 13253 | 90611637 |
| CD4 lymphocytes decreased | 36.06 | 19.26 | 9 | 3548 | 1538 | 90623352 |
| Plasma cell myeloma | 34.69 | 19.26 | 21 | 3536 | 40807 | 90584083 |
| Intussusception | 34.09 | 19.26 | 8 | 3549 | 1057 | 90623833 |
| Smooth muscle cell neoplasm | 32.07 | 19.26 | 8 | 3549 | 1365 | 90623525 |
| Diarrhoea | 24.06 | 19.26 | 86 | 3471 | 939104 | 89685786 |
| Chronic graft versus host disease | 23.35 | 19.26 | 8 | 3549 | 4131 | 90620759 |
| Herpes zoster | 22.70 | 19.26 | 23 | 3534 | 94621 | 90530269 |
| Necrotising retinitis | 22.26 | 19.26 | 5 | 3552 | 544 | 90624346 |
| Acute myeloid leukaemia | 21.17 | 19.26 | 12 | 3545 | 20628 | 90604262 |
| Pericardial drainage | 19.46 | 19.26 | 4 | 3553 | 286 | 90624604 |
| Post transplant lymphoproliferative disorder | 19.31 | 19.26 | 8 | 3549 | 6941 | 90617949 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ureaplasma infection | 47.76 | 22.70 | 10 | 2080 | 626 | 42618619 |
| Febrile neutropenia | 42.95 | 22.70 | 49 | 2041 | 185654 | 42433591 |
| Herpes simplex pneumonia | 42.91 | 22.70 | 8 | 2082 | 274 | 42618971 |
| Gastrointestinal tract mucosal pigmentation | 37.17 | 22.70 | 8 | 2082 | 571 | 42618674 |
| Meralgia paraesthetica | 33.53 | 22.70 | 6 | 2084 | 163 | 42619082 |
| Tuberculosis liver | 31.88 | 22.70 | 5 | 2085 | 59 | 42619186 |
| Lip haemorrhage | 28.37 | 22.70 | 7 | 2083 | 913 | 42618332 |
| Hyperammonaemia | 22.96 | 22.70 | 10 | 2080 | 7856 | 42611389 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Aplastic anaemia | 58.52 | 17.99 | 26 | 4758 | 24282 | 110560233 |
| Febrile neutropenia | 45.54 | 17.99 | 62 | 4722 | 316705 | 110267810 |
| Herpes simplex pneumonia | 41.26 | 17.99 | 8 | 4776 | 385 | 110584130 |
| Ureaplasma infection | 40.15 | 17.99 | 10 | 4774 | 1536 | 110582979 |
| Herpes zoster | 32.32 | 17.99 | 31 | 4753 | 108348 | 110476167 |
| Gastrointestinal tract mucosal pigmentation | 31.87 | 17.99 | 8 | 4776 | 1269 | 110583246 |
| Tuberculosis liver | 30.07 | 17.99 | 5 | 4779 | 99 | 110584416 |
| CD4 lymphocytes decreased | 29.37 | 17.99 | 9 | 4775 | 2965 | 110581550 |
| Bacteraemia | 27.29 | 17.99 | 19 | 4765 | 42371 | 110542144 |
| Platelet count decreased | 27.05 | 17.99 | 41 | 4743 | 230402 | 110354113 |
| Lip haemorrhage | 26.06 | 17.99 | 7 | 4777 | 1445 | 110583070 |
| Plasma cell myeloma | 22.64 | 17.99 | 20 | 4764 | 62916 | 110521599 |
| Pathogen resistance | 21.82 | 17.99 | 12 | 4772 | 17660 | 110566855 |
| Meralgia paraesthetica | 21.19 | 17.99 | 5 | 4779 | 612 | 110583903 |
| Neuropathy peripheral | 21.17 | 17.99 | 32 | 4752 | 179245 | 110405270 |
| Necrotising retinitis | 20.86 | 17.99 | 6 | 4778 | 1590 | 110582925 |
| Drug resistance | 20.44 | 17.99 | 18 | 4766 | 56356 | 110528159 |
| White blood cell count decreased | 19.11 | 17.99 | 35 | 4749 | 229355 | 110355160 |
| Hyperammonaemia | 18.84 | 17.99 | 10 | 4774 | 13722 | 110570793 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AB09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| ATC | S01AD07 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antivirals |
| FDA MoA | N0000020060 | DNA Polymerase Inhibitors |
| FDA EXT | N0000175459 | Nucleoside Analog |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:36044 | antiviral drug |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:64952 | anti-HSV agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| FDA EPC | N0000180187 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor |
Related Drugs by ATC class:
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
S01AD Antivirals 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Herpes zoster | indication | 4740000 | DOID:8536 |
| Herpes simplex | indication | 88594005 | DOID:8566 |
| Recurrent herpes simplex labialis | indication | 402892009 | |
| Recurrent genital herpes simplex | indication | 402894005 | |
| Suppression of Recurrent Herpes Simplex Infection | indication | ||
| Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients | indication | ||
| Suppression of Recurrent Herpes Simplex Infection in HIV | off-label use | ||
| Prevention of Herpes Zoster in Immunocompromised Patient | off-label use | ||
| Kidney disease | contraindication | 90708001 | DOID:557 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA polymerase catalytic subunit | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
| DNA polymerase catalytic subunit | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4020882 | VUID |
| N0000148380 | NUI |
| D00317 | KEGG_DRUG |
| 4020882 | VANDF |
| C0209227 | UMLSCUI |
| CHEBI:4974 | CHEBI |
| CHEMBL880 | ChEMBL_ID |
| DB00426 | DRUGBANK_ID |
| D000077595 | MESH_DESCRIPTOR_UI |
| 3324 | PUBCHEM_CID |
| 11629 | IUPHAR_LIGAND_ID |
| 6438 | INN_ID |
| QIC03ANI02 | UNII |
| 151733 | RXNORM |
| 119086 | MMSL |
| 1730 | MMSL |
| 4712 | MMSL |
| d03775 | MMSL |
| 004470 | NDDF |
| 387557001 | SNOMEDCT_US |
| 96097002 | SNOMEDCT_US |
| QIC03ANI02 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8117 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8118 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8119 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0705 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0706 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0708 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-706 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-707 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-708 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 33342-024 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 25 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 33342-025 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 33342-026 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-414 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-415 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-416 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-0640 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5905 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 28 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-168 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-168 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| FAMCICLOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3245 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 23 sections |
| FAMCICLOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3246 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 23 sections |
| FAMCICLOVIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3247 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 23 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-998 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 24 sections |
| Famciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-7890 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 64980-349 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 64980-350 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 26 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 64980-351 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 26 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 65862-465 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 65862-466 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 26 sections |
| Famciclovir | Human Prescription Drug Label | 1 | 65862-467 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 26 sections |